New study aims to improve quality of life for older bladder cancer patients

NCT ID NCT06138561

First seen Feb 18, 2026 · Last updated May 12, 2026 · Updated 9 times

Summary

This study looks at two treatment options for people aged 65 and older with advanced bladder cancer who cannot take the chemotherapy drug cisplatin. Researchers want to see which treatment better maintains quality of life and causes fewer side effects. Participants will receive either a carboplatin-based chemotherapy followed by immunotherapy, or a combination of enfortumab vedotin and pembrolizumab. The study also tests whether a simple geriatric questionnaire can help predict how well patients will handle their treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.